Literature DB >> 28673528

Benefit-cost analysis of SBIRT interventions for substance using patients in emergency departments.

Brady P Horn1, Cameron Crandall2, Alyssa Forcehimes3, Michael T French4, Michael Bogenschutz5.   

Abstract

Screening, brief intervention, and referral to treatment (SBIRT) has been widely implemented as a method to address substance use disorders in general medical settings, and some evidence suggests that its use is associated with decreased societal costs. In this paper, we investigated the economic impact of SBIRT using data from Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments (SMART-ED), a multisite, randomized controlled trial. Utilizing self-reported information on medical status, health services utilization, employment, and crime, we conduct a benefit-cost analysis. Findings indicate that neither of the SMART-ED interventions resulted in any significant changes to the main economic outcomes, nor had any significant impact on total economic benefit. Thus, while SBIRT interventions for substance abuse in Emergency Departments may be appealing from a clinical perspective, evidence from this economic study suggests resources could be better utilized supporting other health interventions.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Benefit-cost analysis; Economic evaluation; SBIRT; Substance abuse

Mesh:

Year:  2017        PMID: 28673528      PMCID: PMC5538788          DOI: 10.1016/j.jsat.2017.05.003

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  39 in total

1.  Public health, prevention, and emergency medicine: a critical juxtaposition.

Authors:  Steven L Bernstein; Jason S Haukoos
Journal:  Acad Emerg Med       Date:  2008-02       Impact factor: 3.451

Review 2.  Costs of alcohol screening and brief intervention in medical settings: a review of the literature.

Authors:  Jeremy W Bray; Gary A Zarkin; Jesse M Hinde; Michael J Mills
Journal:  J Stud Alcohol Drugs       Date:  2012-11       Impact factor: 2.582

3.  Brief physician advice for problem drinkers: long-term efficacy and benefit-cost analysis.

Authors:  Michael F Fleming; Marlon P Mundt; Michael T French; Linda Baier Manwell; Ellyn A Stauffacher; Kristen Lawton Barry
Journal:  Alcohol Clin Exp Res       Date:  2002-01       Impact factor: 3.455

4.  Costs of screening and brief intervention for illicit drug use in primary care settings.

Authors:  Gary Zarkin; Jeremy Bray; Jesse Hinde; Richard Saitz
Journal:  J Stud Alcohol Drugs       Date:  2015-03       Impact factor: 2.582

5.  Alcohol interventions for trauma patients treated in emergency departments and hospitals: a cost benefit analysis.

Authors:  Larry M Gentilello; Beth E Ebel; Thomas M Wickizer; David S Salkever; Frederick P Rivara
Journal:  Ann Surg       Date:  2005-04       Impact factor: 12.969

Review 6.  The impact of alcohol, tobacco, and other drug use and abuse in the emergency department.

Authors:  Gail D'Onofrio; Bruce Becker; Robert H Woolard
Journal:  Emerg Med Clin North Am       Date:  2006-11       Impact factor: 2.264

7.  Cost-benefit analysis of drug treatment services: review of the literature*

Authors:  William S. Cartwright
Journal:  J Ment Health Policy Econ       Date:  2000-03-01

8.  Cost-effectiveness analysis of a brief intervention delivered to problem drinkers presenting at an inner-city hospital emergency department.

Authors:  F Michael Kunz; Michael T French; Shahrzad Bazargan-Hejazi
Journal:  J Stud Alcohol       Date:  2004-05

Review 9.  Case management for persons with substance use disorders.

Authors:  M Hesse; W Vanderplasschen; R C Rapp; E Broekaert; M Fridell
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

10.  Program- and service-level costs of seven screening, brief intervention, and referral to treatment programs.

Authors:  Jeremy W Bray; Erin Mallonee; William Dowd; Arnie Aldridge; Alexander J Cowell; Janice Vendetti
Journal:  Subst Abuse Rehabil       Date:  2014-07-01
View more
  7 in total

1.  Feasibility of Brief Screening for At-Risk Gambling in Consumer Credit Counseling.

Authors:  Paul Sacco; Jodi Jacobson Frey; Christine Callahan; Martin Hochheimer; Rachel Imboden; Devon Hyde
Journal:  J Gambl Stud       Date:  2019-12

2.  Start-Up Costs of SBIRT Implementation for Adolescents in Urban U.S. Federally Qualified Health Centers.

Authors:  Carolina Barbosa; Brendan Wedehase; Laura Dunlap; Shannon Gwin Mitchell; Kristi Dusek; Robert P Schwartz; Jan Gryzcynski; Arethusa S Kirk; Marla Oros; Colleen Hosler; Kevin E O'Grady; Barry S Brown
Journal:  J Stud Alcohol Drugs       Date:  2018-05       Impact factor: 2.582

3.  Cost-effectiveness of electronic- and clinician-delivered screening, brief intervention and referral to treatment for women in reproductive health centers.

Authors:  Todd A Olmstead; Kimberly A Yonkers; Steven J Ondersma; Ariadna Forray; Kathryn Gilstad-Hayden; Steve Martino
Journal:  Addiction       Date:  2019-06-28       Impact factor: 6.526

4.  Health Care Utilization After Paraprofessional-administered Substance Use Screening, Brief Intervention, and Referral to Treatment: A Multi-level Cost-offset Analysis.

Authors:  Jason Paltzer; David Paul Moberg; Marguerite Burns; Richard L Brown
Journal:  Med Care       Date:  2019-09       Impact factor: 2.983

Review 5.  Alcohol screening and brief intervention in emergency departments: Review of the impact on healthcare costs and utilization.

Authors:  Carolina Barbosa; Lela R McKnight-Eily; Scott D Grosse; Jeremy Bray
Journal:  J Subst Abuse Treat       Date:  2020-08-04

6.  The short-term impact on economic outcomes of SBIRT interventions implemented in reproductive health care settings.

Authors:  Todd A Olmstead; Steve Martino; Steven J Ondersma; Kathryn Gilstad-Hayden; Ariadna Forray; Kimberly A Yonkers
Journal:  J Subst Abuse Treat       Date:  2020-10-21

Review 7.  Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis.

Authors:  Nicolas Iragorri; Eldon Spackman
Journal:  Public Health Rev       Date:  2018-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.